The company is led by Mark S. Wilson, Engr, MBA, previously founding CEO of MatriSys Bioscience, a leading skin microbiome therapeutics company. Mr. Wilson has 30 years of biopharmaceutical development experience including Hybritech, Pfizer Global R&D, and Halozyme Therapeutics where he brought in the $612 million deal with Hoffman La Roche, turning Halozyme into the $5 ½ billion valuation company it is today.